Persistent Asset Partners’s BridgeBio Pharma BBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-536
Closed -$72K – 347
2025
Q4
$72K Buy
+536
New +$35.2K 0.03% 282

Other funds holding BBIO

Persistent Asset Partners's BBIO Position: Q3 2026 in Review

Persistent Asset Partners increased its BridgeBio Pharma (BBIO) stake by 6,438% in Q3 2026, buying an estimated $2.64M and bringing the position to 34,390 shares worth $2.26M. The position accounts for 0.62% of the portfolio, ranked #26.

Persistent Asset Partners first reported a position in BBIO in Q4 2025 and has held it in 4 quarters since. 468 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Persistent Asset Partners held 34,390 shares of BridgeBio Pharma worth $2.26M as of Q3 2026.
  • Persistent Asset Partners bought 33,864 BridgeBio Pharma shares in Q3 2026, an estimated $2.64M.
  • BridgeBio Pharma made up 0.62% of Persistent Asset Partners's portfolio in Q3 2026, its #26 holding.
  • Persistent Asset Partners first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 4 quarters since.
  • 468 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.